Inhibition of telomerase activity has emerged as a promising strategy to combat cancer cells, especially ones with no specific molecular targets such as triple negative breast cancer (TNBC). Cisplatin, a chemotherapeutic drug, is causing DNA damage while apigenin, a plant-derived antioxidant, induces apoptosis in various cancer cell types. Little is known about their combined ability to inhibit telomerase activity in TNBC cells. In the current study, the effect of cisplatin in combination with apigenin was investigated with regards to telomerase activity and expression of the telomerase catalytic subunit hTERT as well as Heat Shock Protein 90 (Hsp90) and p23 in two types of TNBC (MDA-MB-231; HCC1806) and one non-tumorigenic (MCF10A) epithelial cell line. The results showed that the combined treatment of cisplatin and apigenin significantly down-regulated telomerase activity. The inhibition of telomerase activity was accompanied by a down-regulation of hTERT, Hsp90 and p23 at transcriptional and translational level in both TNBC cells, as compared to control cells. The results of the current study suggest that apigenin and cisplatin synergistically inhibit telomerase activity by downregulating the enzyme’s catalytic subunit. However, the exact roles of Hsp90 and p23 in the regulation of telomerase activity requires further investigation as they seem to be TNBC subtype-specific.